Trials / Completed
CompletedNCT00454883
Non-interventional Study of Ziprasidone in the Treatment of Bipolar and Schizoaffective Disorders.
Treatment Of Manic Or Mixed Episodes Of Up To Moderate Severity In Patients With Bipolar Disorder And Schizoaffective Disorder
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 379 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Assessment of ziprasidone safety and efficacy in the treatment of bipolar and schizoaffective disorders.
Detailed description
Method: Consecutive patient sampling. Patients were included in the study in consecutive manner if they fulfilled the inclusion criteria and any of the exclusion criteria were not present.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ziprasidone | Ziprasidone 40 mg twice daily taken with food. Daily dosage may subsequently be adjusted on the basis of individual clinical status up to a maximum of 80 mg twice daily. If indicated, the maximum recommended dose may be reached as early as day 3 of treatment. |
Timeline
- Start date
- 2007-04-01
- Primary completion
- 2007-12-01
- Completion
- 2007-12-01
- First posted
- 2007-04-02
- Last updated
- 2021-02-21
Source: ClinicalTrials.gov record NCT00454883. Inclusion in this directory is not an endorsement.